For Investors
A platform-stage oncology asset
CCI-001 is a clinic-stage, IP-protected, multi-indication targeted cancer therapy with a tolerability profile that conventional tubulin inhibitors cannot offer.
Phase 1
Active clinical trial in bladder cancer
Multi-indication
Bladder, breast, with broader oncology potential
IP protected
Granted patents in US, Canada and Europe
International
Collaborators across 6+ countries
The opportunity
Bladder cancer represents a multi-billion dollar global market with limited innovation in targeted therapy. Breast cancer expands the addressable market substantially. CCI-001's selectivity profile positions it for combination regimens and earlier-line use where current tubulin inhibitors are limited by toxicity.
Highlights
- • Composition-of-matter patents in major markets through the late 2030s
- • De-risked mechanism - colchicine-class biology with novel selectivity
- • Strong academic foundation - University of Alberta and international collaborators
- • Pipeline expansion into breast and additional oncology indications
How we engage
We work with strategic investors, family offices, and industry partners interested in clinic-stage oncology assets. Reach out for our investor brief, current data package, and corporate presentation under NDA.
- Investor brief & corporate deck
- Phase 1 protocol and emerging data
- IP and freedom-to-operate summary
- Direct conversations with leadership
Market context
Bladder cancer is the 10th most common cancer worldwide, with roughly 600,000 new cases diagnosed each year and high recurrence rates that drive long-term treatment costs. Breast cancer remains the most diagnosed cancer in women globally. Both indications have growing demand for targeted therapies that can replace or complement broad-spectrum cytotoxics.
CCI-001's selectivity for βIII-tubulin - an isotype enriched in cancer cells but largely absent from healthy tissue - addresses the central limitation of existing tubulin inhibitors: dose-limiting toxicity. This profile supports use in combination regimens, earlier lines of therapy, and patient populations who cannot tolerate taxanes or vinca alkaloids.
IP & freedom to operate
- USPTO - composition-of-matter patent allowed June 1, 2016 (PCT/CA2010/001199).
- CIPO (Canada) - allowed October 18, 2017.
- EPO (Europe) - allowed December 4, 2017.
- Coverage extends to novel colchicine derivatives, methods of synthesis and oncology uses, providing protection across our lead and follow-on compounds.
Use of capital
- • Complete Phase 1 dose-escalation and expansion in bladder cancer
- • IND-enabling work for the breast cancer indication
- • Manufacturing scale-up and regulatory readiness
- • Selective expansion of the preclinical pipeline against βIII-enriched tumors
Why now
We are at the inflection point between a fully de-risked preclinical package and the first clinical signal in patients. The forthcoming May 21 publication consolidates a decade of foundational science and provides the data backbone investors need to underwrite the next phase of development.
What's next
From Phase 1 signal to commercial path
Phase 2 planning
Designing the next study in bladder cancer and preparing the breast cancer indication for IND-enabling work.
Strategic partnerships
Open to investment, co-development, and out-licensing conversations with pharma and strategic partners.
Pipeline expansion
Selectively advancing additional βIII-tubulin–enriched indications behind the lead asset.
Investment opportunity
A clinic-stage asset with a defined path to value
CCI-001 is a Phase 1 targeted oncology asset with composition-of-matter patents in the US, Canada, and Europe, an active trial in bladder cancer, and a pipeline that extends naturally into breast cancer and other βIII-tubulin–enriched tumors. We are raising to complete the Phase 1 readout, advance the breast indication into IND-enabling work, and scale manufacturing for Phase 2.
Stage
Phase 1 - bladder
Active dose-escalation
Indications
Bladder, breast
Pipeline expansion underway
IP
US · CA · EU
Composition-of-matter to late 2030s
Use of funds
Phase 1 → Phase 2
Trial, IND-enabling, CMC
Why this asset, why now
- First clinical signal expected from Phase 1; the May 21 publication consolidates the preclinical package.
- Selective for βIII-tubulin - addresses the central toxicity limit of taxanes and vinca alkaloids.
- Multi-indication potential supports combination, earlier-line, and platform plays.
- Strong academic foundation - University of Alberta and an international collaborator network.
Available on request
- Investor brief & corporate deck
- Phase 1 protocol and emerging data summary
- IP and freedom-to-operate overview
- Direct conversation with leadership
Non-public materials are shared under a mutual NDA. Indicate this on the form below.
Investor inquiry
Request the investor brief, corporate deck, or schedule an introductory call. The IR team will follow up by email.
This page is provided for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities. Any such offer would be made only by means of formal offering documents.